The original success of Sildenafil undeniably reshaped the pharmaceutical landscape, but investing in companies strongly reliant on generic versions presents a challenging picture. Although early earnings were significant, the end of patents and the emergence of cheaper alternatives have diminished market share. Consequently, a thorough assessment